IJMS | Free Full-Text | Possible Link between Higher Transmissibility of Alpha, Kappa and Delta Variants of SARS-CoV-2 and Increased Structural Stability of Its Spike Protein and hACE2 Affinity | HTML
Differential Interactions Between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern | bioRxiv
Differential Interactions between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern | Journal of Chemical Theory and Computation
Kappa-RBD produced by glycoengineered Pichia pastoris elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants - ScienceDirect
Frontiers | I mmunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People | Immunology
Viruses | Free Full-Text | Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight | HTML
Emerging Vaccine-Breakthrough SARS-CoV-2 Variants | ACS Infectious Diseases
Kappa - Wikipedia
Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant
Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance | Journal of Chemical Information and Modeling
Frontiers | The Pathogenic Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Possible Mechanisms for Immune Evasion? | Immunology
Hidden in plain sight: The effects of BCG vaccination in the COVID‐19 pandemic - Toraih - 2021 - Journal of Medical Virology - Wiley Online Library
Takashi Murakami - Evening & Day Ed... Lot 254 January 2020 | Phillips
SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021 | Microbiology Spectrum
Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion | mBio
Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection - ScienceDirect
SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera - ScienceDirect
Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion | mBio
Projects | Smurfit Kappa Foundation
Thrombosis in COVID‐19 - Hanff - 2020 - American Journal of Hematology - Wiley Online Library
Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2 | Journal of Natural Products
Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant | The Journal of Physical Chemistry Letters
Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron - ScienceDirect
CD11b Antibody, FITC (11-0112-41)
Differential Interactions Between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern
